Memo Therapeutics made it to the top 100 of Swiss startups for the third time in a row and is …

Memo Therapeutics AG was awarded a new CTI grant
MEMO has secured a third CTI …

Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform
 
Basel/Zurich, Switzerland, May 23, …

MEMO at conferences
MEMO presented in the investment stream at SNB 2017 in Zurich this year. Link to the conference …

Memo Therapeutics AG announces completion of a first commercial project validating its proprietary MemoMAB™ antibody technology platform.
Basel/Zurich, …

MEMO’s poster introducing the MemoMAB™ technology platform for the banking and screening of human immunoreceptor libraries was selected for the …

MEMO’s abstract has been accepted for Poster Discussion presentation during the ESMO Symposium on Immuno-Oncology – Advances in cancer immunotherapy; …

Memo Therapeutics made it to the top 100 of Swiss startups for the second time in a row and is …

2016 Meeting Schedule
 
Sept 27-28: SACHS 16th Annual Biotech in Europe Forum, Basel
MEMO’s CEO Dr. A. Mäder will …

MEMO has started a first client project based on its rbMemoMAB™ antibody discovery technology.
About rbMemoMAB™.